KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Amortization - Intangibles for 7 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles rose 34.43% to $24.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.4 million through Dec 2025, up 14.75% year-over-year, with the annual reading at $89.5 million for FY2025, 14.72% up from the prior year.
  • Amortization - Intangibles for Q4 2025 was $24.5 million at Supernus Pharmaceuticals, up from $24.3 million in the prior quarter.
  • The five-year high for Amortization - Intangibles was $24.5 million in Q4 2025, with the low at $5.9 million in Q2 2021.
  • Average Amortization - Intangibles over 5 years is $18.1 million, with a median of $20.1 million recorded in 2023.
  • The sharpest move saw Amortization - Intangibles surged 375.81% in 2021, then fell 13.41% in 2024.
  • Over 5 years, Amortization - Intangibles stood at $12.0 million in 2021, then skyrocketed by 71.72% to $20.7 million in 2022, then increased by 1.94% to $21.1 million in 2023, then decreased by 13.41% to $18.2 million in 2024, then soared by 34.43% to $24.5 million in 2025.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $24.5 million, $24.3 million, and $20.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.